A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2001 participants.
Also called NCT07794579
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,001 participants
- Sponsor
- Registry
-
NCT07794579 -
2026-526175-35-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South Korea, Spain, Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT07794579. Randomized; double masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2029-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Acronym
- ATTAIN-NOW
- Condition
- Overweight
- Condition
- Prediabetic State
- Condition
- Prehypertension
- Condition
- Obesity, Abdominal
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07794579- Content hash
95e536c9379a13cb9ded547b1fc4f1cfbcb4aeb9c2358f448194c63a42cb78d8